Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.

Recruiting N/A Interventional Study
Neuromyelitis Optica Spectrum Disorders MOGAD Multiple Sclerosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
50 (estimated)
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in a a comparison group of patients affected with Multiple Sclerosis (MS). The study will involve adult patients diagnosed with MS, NMOSD, or MOGAD, followed at various cli…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adult patients diagnosed with MS, NMOSD, or MOGAD receiving care at participating centers * Patients aged ≥ 18 years * Ability to understand and sign informed consent Exclusion Criteria: * Individuals under 18 years of age * Inability to provide informed consent
Contacts

Massimiliano Mirabella, Neurology Associate Professor

0630155390

massimiliano.mirabella@policlinicogemelli.it

CONTACT